Jones Financial Companies
INKT icon

Jones Financial Companies’s MiNK Therapeutics INKT Stock Holding History

Jones Financial Companies’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12 Hold
1
– – ﹤0.01% 4934
2026
Q1 		$11 Hold
1
– – ﹤0.01% 4697
2025
Q4 		$11 Hold
1
– – ﹤0.01% 4375
2025
Q3 		$14 Hold
1
– – ﹤0.01% 4209
2025
Q2 		$7 Hold
1
– – ﹤0.01% 4018
2025
Q1 		$9 Buy
+1
New +$9 ﹤0.01% 3687

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Steward Partners Investment Advisory
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Jones Financial Companies's INKT Position: Q2 2026 in Review

Jones Financial Companies held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 1 share worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #4934.

Jones Financial Companies first reported a position in INKT in Q1 2025 and has held it in 6 quarters since. The position peaked at $14 in Q3 2025. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Jones Financial Companies held 1 share of MiNK Therapeutics worth $12 as of Q2 2026.
  • Jones Financial Companies left its MiNK Therapeutics share count unchanged in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4934 holding.
  • Jones Financial Companies first reported a position in MiNK Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Jones Financial Companies's MiNK Therapeutics position peaked at $14 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.